Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Acadia Hospital
mi
from
Bangor, ME
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Acadia Hospital
mi
from
Bangor, ME
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Quantum Laboratories
mi
from
Deerfield Beach, FL
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Quantum Laboratories
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Clinical Research Network
mi
from
San Diego, CA
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Clinical Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Unit
mi
from
Washington,
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Unit
mi
from
Washington,
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Ani Neurology, PLLC dba Alzheimer's Memory Ctr
mi
from
Charlotte, NC
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Ani Neurology, PLLC dba Alzheimer's Memory Ctr
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pharmaceutical Research Associates Inc.
mi
from
Salt Lake City, UT
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pharmaceutical Research Associates Inc.
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Collier Neurologic Specialists
mi
from
Naples, FL
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Collier Neurologic Specialists
mi
from
Naples, FL
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Psicomed Estudios Médicos
mi
from
Antofagasta,
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Psicomed Estudios Médicos
mi
from
Antofagasta,
Click here to add this to my saved trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Disease Center
mi
from
Quincy, MA
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Disease Center
mi
from
Quincy, MA
Click here to add this to my saved trials
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of myMS in Participants With a Diagnosis of Multiple Sclerosis
A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Aimslab@Usc.Edu
mi
from
Los Angeles, CA
Study of myMS in Participants With a Diagnosis of Multiple Sclerosis
A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Aimslab@Usc.Edu
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations
Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations
Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations
Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies
Status: Enrolling
Updated:  12/31/1969
Associacao dos Gemeos do Norte de Minas Gerais
mi
from
Minas Gerais,
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations
Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies
Status: Enrolling
Updated: 12/31/1969
Associacao dos Gemeos do Norte de Minas Gerais
mi
from
Minas Gerais,
Click here to add this to my saved trials
Central Nervous System Disease in HIV-infected Children on HAART
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Central Nervous System Disease in HIV-infected Children on HAART
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)
PET Scanning of Brain Dopaminergic Signal Transduction Involving Arachidonic Acid in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)
PET Scanning of Brain Dopaminergic Signal Transduction Involving Arachidonic Acid in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
P-glycoprotein Function in Brain Diseases
Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
P-glycoprotein Function in Brain Diseases
Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Medication Management Among Individuals With Neurodevelopmental Disabilities
Medication Management Among Individuals With Neurodevelopmental Disabilities
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Medication Management Among Individuals With Neurodevelopmental Disabilities
Medication Management Among Individuals With Neurodevelopmental Disabilities
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dexamethasone Versus Depo Medrol in Lumbar Epidurals
A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections
Status: Enrolling
Updated:  12/31/1969
Upstate Orthpedics
mi
from
East Syracuse, NY
Dexamethasone Versus Depo Medrol in Lumbar Epidurals
A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections
Status: Enrolling
Updated: 12/31/1969
Upstate Orthpedics
mi
from
East Syracuse, NY
Click here to add this to my saved trials
An Online Mindfulness Intervention for People With ALS and Their Caregivers
An Online Mindfulness Intervention for People With ALS and Their Caregivers
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
An Online Mindfulness Intervention for People With ALS and Their Caregivers
An Online Mindfulness Intervention for People With ALS and Their Caregivers
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Timing of VTE Prophylaxis in TBI
Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Timing of VTE Prophylaxis in TBI
Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Diet, Insulin Sensitivity, and Postprandial Metabolism
A Randomized, Controlled Trial on Diet, Insulin Sensitivity, and Postprandial Metabolism
Status: Enrolling
Updated:  12/31/1969
Physicians Committee for Responsible Medicine
mi
from
Washington,
Diet, Insulin Sensitivity, and Postprandial Metabolism
A Randomized, Controlled Trial on Diet, Insulin Sensitivity, and Postprandial Metabolism
Status: Enrolling
Updated: 12/31/1969
Physicians Committee for Responsible Medicine
mi
from
Washington,
Click here to add this to my saved trials
ALS Testing Through Home-based Outcome Measures
ALS Testing Through Home-based Outcome Measures (ALS AT HOME)
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
ALS Testing Through Home-based Outcome Measures
ALS Testing Through Home-based Outcome Measures (ALS AT HOME)
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oral Fecal Transplant in Cirrhosis
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Oral Fecal Transplant in Cirrhosis
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Oral Fecal Transplant in Cirrhosis
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Oral Fecal Transplant in Cirrhosis
Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated:  12/31/1969
Lyerly Baptist
mi
from
Jacksonville, FL
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated: 12/31/1969
Lyerly Baptist
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated:  12/31/1969
University at Buffalo
mi
from
Buffalo, NY
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated: 12/31/1969
University at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Health Science Center
mi
from
Memphis, TN
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Birmingham, AL
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Gilbert, AZ
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site 1
mi
from
Phoenix, AZ
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site 1
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Bakersfield, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Long Beach, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Orange, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Rolling Hills Estates, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
San Diego, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Santa Rosa, CA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Centennial, CO
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Centennial, CO
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Denver, CO
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Washington,
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Tampa, FL
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Macon, GA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Sandy Springs, GA
Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Sandy Springs, GA
Click here to add this to my saved trials